MedTrace Logo

The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer

NCT02038621 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2014-01-16

No results posted yet for this study

Summary

To confirm the efficacy and safety of XELOX with capecitabine maintenance in treatment of advanced gastric cancer (AGC)

Conditions

  • Advanced Gastric Cancer

Interventions

DRUG

Paclitaxel

DRUG

Oxaliplatin and Capecitabine

Before randomization,all enrolled patients underwent 3 cycles XELOX chemotheray. After patients' disease achieved CR\\PR\\SD,then randomized into this clinical trial.

Sponsors & Collaborators

  • The Second People's Hospital of Sichuan

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2016-12-31
Completion
2017-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02038621 on ClinicalTrials.gov